Join
Live feed
·
PRReleasevia Quantisnow
Bio-Techne Corp logo

Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative

ByQuantisnow·Wall Street's wire, on your screen.
TECH· Bio-Techne Corp
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TECH (Bio-Techne Corp) and more on Quantisnow.